Compare McKesson Corporation (MCK) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? McKesson Corporation trades at $859.16 (market cap $102.45B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.66. The key difference: McKesson Corporation pays a 0.43% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | VOOG | |
|---|---|---|
Market Cap | $102.45B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $85.42 |
52-Week Low | $663.17 | $65.32 |
Enterprise Value | $108.99B | — |
Dividend Yield | 0.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $856.69, down 5.0% over the past day, amid a generally positive fundamental backdrop. The stock shows strong technical support near $851-$870 with bullish moving average signals. Recent Q1 2027 earnings beat expectations with EPS of $9.93 versus $9.56 expected, driven by specialty drug and oncology growth, prompting the company to raise full-year guidance. Revenue reached $359.05 billion in 2025 with net income of $3.30 billion, though margins remain thin at 1.12%.
The outlook remains favorable with 80% analyst buy ratings and a consensus price target of $990.67, suggesting 15.6% upside. Key risks include competitive pressures in pharmaceutical distribution and reliance on specialty drug trends. Cash flow trends improved significantly in 2025 with net cash flow of $1.37 billion, supporting dividend payments and operational flexibility.
VOOG trades at $85.05, up 0.43% today and near its 52-week high, with a strong bullish technical signal from moving averages. The ETF's growth focus on large-cap stocks, particularly in technology, and its low expense ratio of 0.07% (The Motley Fool, 2026-07-25) attract institutional interest, as seen in recent filings from Apella Capital LLC (Defense World, 2026-08-07).
Outlook remains positive due to momentum and cost efficiency, but risks include tech sector concentration and overbought conditions. Investors should weigh growth potential against valuation sensitivity and market volatility for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
